Phosphodiesterase 3 inhibitors boost bone outgrowth
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Takaaki Kawabe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Kyoto, Japan. Hauptthemen laut MEDLINE: Phosphodiesterase 3 Inhibitors, Bone Development. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kobayashi International Scholarship Foundation, Nakatomi Foundation, Mother and Child Health Foundation.
Abstract (Originalsprache)
Background and Purpose C‐type natriuretic peptide (CNP) stimulates skeletal growth by acting on the growth plates of long bones, and a CNP variant is clinically used for achondroplasia treatment. We previously reported that CNP stimulates the autonomic Ca 2+ influx mediated by TRPM7 channels in growth plate chondrocytes to facilitate extracellular matrix synthesis for bone growth. In this study, we attempted to stimulate CNP signalling using phosphodiesterase (PDE) inhibitors. Experimental Approach Based on gene expression data, we focused on the role of PDE3B in growth plates. We performed imaging, biochemical and histological analyses in growth plate chondrocytes and ex vivo and in vivo analyses on bone and skeletal growth to address the pharmacological effects of PDE3 inhibitors. Key Results The representative PDE3 inhibitors cilostazol and milrinone elevated cGMP levels and activated cell‐surface K + channels probably due to protein kinase G‐mediated phosphorylation in growth plate chondrocytes. The resulting hyperpolarization likely facilitated TRPM7‐mediated Ca 2+ influx by increasing the Ca 2+ ‐driving force. Moreover, cilostazol stimulated the elongation of cultured bones and enlarged the body size of juvenile mice. Conclusion and Implications Several PDE3 inhibitors have been used for clinical treatment of thrombosis, heart failure and asthma, while our observations suggest that the repositioning of PDE3 inhibitors would provide novel medications for skeletal diseases characterized by short stature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Kyoto, Japan.
- Laboratory of Integrative Physiology, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
- Protein Research Foundation, Osaka, Japan.
- National Cerebral and Cardiovascular Center, Osaka, Japan.
- Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Orthopedic Surgery, Kurashiki Central Hospital, Okayama, Japan.
ORCID-Profile: Atsuhiko Ichimura
Förderung
- Kobayashi International Scholarship Foundation
- Nakatomi Foundation
- Mother and Child Health Foundation
- Japan Foundation for Applied Enzymology
- Platform Project for Supporting Drug Discovery and Life Science Research
- Takeda Medical Research Foundation
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Kawabe, T., Ichimura, A., Yasue, T., Li, J., Ishikawa, H., Kim, G. E., Nagatomo, H., Minamino, N., Ueda, Y., Ito, H., Nishi, M., & Takeshima, H. (2025). Phosphodiesterase 3 inhibitors boost bone outgrowth. British Journal of Pharmacology. https://doi.org/10.1111/bph.70087
Vancouver
Kawabe T, Ichimura A, Yasue T, Li J, Ishikawa H, Kim GE, et al. Phosphodiesterase 3 inhibitors boost bone outgrowth. British Journal of Pharmacology. 2025. doi:10.1111/bph.70087
BibTeX
@article{Kawabe2025,
author = {Kawabe, Takaaki and Ichimura, Atsuhiko and Yasue, Tomoki and Li, Jianhong and Ishikawa, Haruki and Kim, Ga Eun and Nagatomo, Hiroki and Minamino, Naoto and Ueda, Yohei and Ito, Hiromu and Nishi, Miyuki and Takeshima, Hiroshi},
title = {Phosphodiesterase 3 inhibitors boost bone outgrowth},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70087}
}
EUVIMED